Tag: stem cell

[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Stem Cell Culture Media Market size & share revenue was valued at approximately USD 765 Million in 2025 and is expected to reach USD 868 Million in 2026 and is expected to reach around USD 2714 Million by 2035, at a CAGR of 13.5% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are PAN Biotech GmbH, Sartorius AG, Cytiva, Lonza Group AG, Corning Incorporated, STEMCELL Technologies Inc., FUJIFILM Irvine Scientific Inc., Takara Bio Inc., Miltenyi Biotec B.V. & Co. KG, PromoCell GmbH, Biological Industries Ltd., CellGenix GmbH, Thermo Fisher Scientific Inc., HiMedia Laboratories Pvt. Ltd., Merck KGaA and others.

HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today presented positive results from the Phase 1 healthy participant study of CDX-622, a novel, bispecific antibody that targets soluble SCF and TSLP, at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. Data demonstrated that CDX-622 induced rapid, durable, dose-dependent reductions in serum tryptase, indicative of mast cell depletion, and was well-tolerated at all dose levels. Building on Celldex’s leadership in mast cell science, the data also demonstrated that neutralizing soluble stem cell factor (SCF) enables the potential for meaningful mast cell inhibition and depletion without impacting other KIT-dependent functions. CDX-622 is currently being studied in a Phase 1b proof of mechanism study in mild to moderate asthma to assess the impact of dual neutralization of SCF and TSLP.

ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct GLORA-4 study (NCT06641414), a global registrational Phase III study of lisaftoclax (APG-2575), a proprietary Bcl-2 inhibitor, in combination with azacitidine (AZA), for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).

The stem cell banking market is booming due to advancements in tech and regenerative medicine, rising healthcare spend, private investments, and ethical shifts favoring adult stem cells. Key opportunities lie in personalized healthcare, clinical trials, and expanding access globally, with North America leading market growth.